PMID- 36466901
OWN - NLM
STAT- MEDLINE
DCOM- 20231006
LR  - 20231006
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 13
DP  - 2022
TI  - Indirubin combined with umbilical cord mesenchymal stem cells to relieve 
      psoriasis-like skin lesions in BALB/c mice.
PG  - 1033498
LID - 10.3389/fimmu.2022.1033498 [doi]
LID - 1033498
AB  - OBJECTIVE: To investigate the efficacy of indirubin combined with human umbilical 
      cord mesenchymal stem cells (hUC-MSCs) in the treatment of psoriatic lesions in 
      BALB/c mice and to explore the related mechanism of indirubin in the treatment of 
      psoriasis. METHODS: A BALB/c mouse psoriasis model induced by imiquimod was 
      established and randomly divided into the control group, model group, indirubin 
      group, hUC-MSCs group, and indirubin combined with hUC-MSCs group. Psoriasis area 
      and severity index (PASI) score was used to observe skin lesion changes in the 
      psoriasis-like mouse model. The epidermal scale, the degree of keratinization, 
      and the infiltration of inflammatory cells were observed by hematoxylin eosin 
      (HE) staining. The concentrations of TNF-alpha, IFN-gamma, IL-17A, and IL-23 in serum of 
      mice were measured using enzyme-linked immunosorbent assay (ELISA). RESULTS: The 
      PASI integral trend chart indicates that hUC-MSCs and indirubin and the 
      combination of drugs could relieve the appearance of skin lesions and accelerate 
      the recovery of skin lesions. The indirubin group had the best effect in 
      improving the scale of skin lesions. HE staining showed that the number of 
      parakeratosis cells in the three treatment groups was significantly reduced, the 
      degree of erythrocyte extravasation dermis hyperplasia and inflammatory cell 
      infiltration was significantly lower than that in the model group, and the skin 
      thickness and spleen index of the combined treatment group exhibited the most 
      noticeable improvement. ELISA showed that the concentrations of TNF-alpha, IFN-gamma, 
      IL-17A, and IL-23 in serum of mice in the hUC-MSCs treatment group, indirubin 
      group, and combined administration group were all decreased compared with those 
      in the model group, and the concentrations of IFN-gamma, IL-17A, and IL-23 could be 
      decreased significantly in the indirubin group. CONCLUSIONS: Both hUC-MSCs and 
      indirubin can effectively reduce psoriasis-like lesions in BALB/c mice, and the 
      combined administration of these drugs has the best effect.
CI  - Copyright (c) 2022 Lu, Wang, Wang, Xie, Jiang, Shen, Zhang, Yang and Lin.
FAU - Lu, XiaoJuan
AU  - Lu X
AD  - Department of Dermatology, Guangzhou Red Cross Hospital of Jinan University, 
      Guangzhou, China.
FAU - Wang, Hao
AU  - Wang H
AD  - Lab Animal Research Center, Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 
      Shanghai, China.
FAU - Wang, Hongwei
AU  - Wang H
AD  - Lab Animal Research Center, Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 
      Shanghai, China.
FAU - Xie, Fan
AU  - Xie F
AD  - Lab Animal Research Center, Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 
      Shanghai, China.
FAU - Jiang, Cuibao
AU  - Jiang C
AD  - Lab Animal Research Center, Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 
      Shanghai, China.
FAU - Shen, Danpeng
AU  - Shen D
AD  - Lab Animal Research Center, Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 
      Shanghai, China.
FAU - Zhang, Hongpeng
AU  - Zhang H
AD  - Lab Animal Research Center, Asia Stem Cell Regenerative Pharmaceutical Co. Ltd., 
      Shanghai, China.
FAU - Yang, Jie
AU  - Yang J
AD  - Department of Dermatology, The Fifth People's Hospital of Hainan Province, 
      Haikou, China.
FAU - Lin, Youshu
AU  - Lin Y
AD  - Department of Dermatology, The Fifth People's Hospital of Hainan Province, 
      Haikou, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20221116
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - V86L8P74GI (indirubin)
RN  - 0 (Interleukin-17)
RN  - 0 (Interleukin-23)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Mice
MH  - Interleukin-17
MH  - Interleukin-23
MH  - *Mesenchymal Stem Cells
MH  - Mice, Inbred BALB C
MH  - *Psoriasis/therapy
MH  - *Skin Diseases/therapy
MH  - Tumor Necrosis Factor-alpha
MH  - Umbilical Cord
MH  - Human Umbilical Vein Endothelial Cells
MH  - Humans
PMC - PMC9709816
OTO - NOTNLM
OT  - combined administration
OT  - indirubin
OT  - inflammatory factor
OT  - psoriasis
OT  - umbilical cord mesenchymal stem cells
COIS- Authors HW, HW, FX, CJ, DS, and HZ were employed by Asia Stem Cell Regenerative 
      Pharmaceutical Co. Ltd. The remaining authors declare that the research was 
      conducted in the absence of any commercial or financial relationships that could 
      be construed as a potential conflict of interest.
EDAT- 2022/12/06 06:00
MHDA- 2022/12/07 06:00
PMCR- 2022/01/01
CRDT- 2022/12/05 04:13
PHST- 2022/08/31 00:00 [received]
PHST- 2022/10/28 00:00 [accepted]
PHST- 2022/12/05 04:13 [entrez]
PHST- 2022/12/06 06:00 [pubmed]
PHST- 2022/12/07 06:00 [medline]
PHST- 2022/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2022.1033498 [doi]
PST - epublish
SO  - Front Immunol. 2022 Nov 16;13:1033498. doi: 10.3389/fimmu.2022.1033498. 
      eCollection 2022.